Methotrexate Drugs Market Share

North America Market Insights

North America in the methotrexate drugs market is projected to garner the largest share of 35.5% by the end of 2035. The market’s growth in the region is highly attributed to a surge in autoimmune diseases, including psoriasis and arthritis, progressive healthcare facilities across different countries, the presence of notable pharma manufacturers, tactical collaborations, an increase in patient awareness, and administrative support. As per the 2025 National Psoriasis Foundation article, the disease affects approximately 3.0% of the adult population, particularly in the U.S., which accounts for over 7.5 million adults. Additionally, an estimated 600,000 adults in the country reside with undiagnosed psoriasis, thereby bolstering the market’s growth in the region.

The market in the U.S. is growing effectively, owing to the aspect of the highest population with autoimmune incidences, suitable reimbursement policies, aging demographics driving the drug demand, focus on research and developmental activities, robust industrial presence, and comprehensive insurance coverage. As per an article published by NLM in December 2024, more than 15 million, which is 4.6% of the country’s population are diagnosed with at least 1 autoimmune disorder as of June 2022. In addition, almost 34% are diagnosed with more than 1 autoimmune disease, with 63% of females being readily affected, thus suitable for the market’s development.

The methotrexate drugs market in Canada is uplifting due to generous grant provision by the government, stabilized growth, owing to suitable federal health and medical budgets, advanced health infrastructure, early diagnosis service, provincial-level investment, effective deals with industrial associations, and competitive market presence. According to a report published by the Government of Canada in 2023, the Musculoskeletal Health and Arthritis Institute provided USD 100,000 to ensure relevant research and mandate priorities between 2022 and 2023, thereby symbolizing a huge growth opportunity for the market in the country.

Arthritis Incidence in North America (2022-2023)

Sources: CDC, February 2024; Arthritis Society Canada, 2025

APAC Market Insights

Asia Pacific in the methotrexate drugs market is expected to emerge as the fastest-growing region during the predicted timeline. The market’s exposure in the region is highly fueled by rapid improvement in healthcare infrastructure and medical expenditure, an upsurge in chronic autoimmune diseases, extension of medical protocols in the West, the presence of policy reforms, and an increase in pharmaceutical market penetration. As per a data report published by ADB in June 2025, over 20 countries in the region constitute 20% higher risk of people facing death, owing to chronic conditions. However, to keep a check on this, an early screening program reached almost 40% of the population in Mongolia, thereby creating an optimistic approach for the market.

The market in China is gaining increased traction, owing to government-based healthcare strategies targeting rare diseases, the NMPA’s support for regional and fast-track manufacturing approvals, an increase in diagnosed patients, and a surge in insurance coverage. As per the February 2023 Journal of the American Medical Directors Association article, the domestic prevalence of any chronic disorder has been 81.1%, which accounts for 179.9 million adult patients. However, there has been an increase in the prevalence between 80 to 84 years of age, thus denoting a positive outlook for the market’s demand in the country.

The methotrexate drugs market in India is developing due to the presence of an underserved patient population, priority for national insurance, along with cost-effective therapies for chronic diseases, generous investment in pharmaceutical manufacturing, and extension of government subsidies for crucial drugs. According to the May 2023 NLM article, the healthcare system in the country is extremely diversified and comprises a network of private and public sectors, while providing suitable medical services to 1.4 billion inhabitants. Besides, the Ayushman Bharat scheme provides almost INR 5 Lakhs coverage per family every year, thus bolstering the market’s exposure.

2022 Healthcare Expenditure in the Asia Pacific

Source: World Bank Data, 2025

Europe Market Insights

Europe in the methotrexate drugs market is considered to account for a considerable market share by the end of the forecast timeline. The market’s exposure in the region is highly driven by suitable advancements in technology, ongoing innovation in optimizing drug formulations, diversified healthcare sectors, robust government support, and acceleration in research and development. According to the September 2024 ECIPE article, technology diffusion in healthcare caters to 2.5% of innovators, 13.5% early adopters, and 34% early majority. Besides, the 2025 Europe Commission data report stated that 100% of the region’s citizens will gain access to online medical records through e-health, as well as a digitalized ID card.

The methotrexate drugs industry in Germany is gaining increased exposure, owing to the aspect of government spending, wide-range patient accessibility, increased biosimilars penetration, integrated real-world evidence, and active participation in the regional pharmaceutical policy and advanced programs. According to a data report published by ITA in August 2025, the Horizon Europe program, since its initiation, readily supports R&D activities, particularly for cancer treatments by utilizing digital, aging, smart health, and generative AI models, along with USD 8.9 million EU4MEDTECH to streamline administrative pathways. Besides, the aging population suffering from chronic diseases, and all these factors denote an optimistic outlook for the overall market in the country.

The methotrexate drugs market in the UK is also growing due to the provision of wide accessibility and reimbursement rates by the NHS-based universal healthcare policy, government reforms focusing affordable prescribing aspect, robust digital health facility, and continuous private and public investments in patient education and pharmaceutical R&D. According to an article published by the Department of Health and Social Care in November 2022, an estimated 53% of NHS consultants in the country undertook private practice, with approximately 3,000 overall operating in the private sector, thus denoting a positive outlook for the market’s growth.